Table 1 |
||||
|
Outpatient Addiction Pharmacotherapy |
||||
| Drug of Abuse |
Prescription Medication |
Usual SIG |
Notes |
Support Systems |
|
|
||||
| Tobacco |
a) Nicotine Substitution NTS1 Polacrilex gum Nasal spray Inhaler Lozenge b) Buproprion SR |
a) various dosing protocols. b) 150 mg once daily × 3 days then; 150 mg B.I.D. |
a) Stop tobacco use before initiating treatment b) Contraindicated in patients with a history of bulimia, anorexia nervosa, seizure, or currently taking an MAOI or another product containing buproprion. |
Nicotine Anonymous http://www.nicotine-anonymous.org webcite American Lung Association http://www.lungusa.org webcite American Cancer Society http://www.cancer.org webcite American Heart Association http://www.americanheart.org webcite |
| Alcohol |
a) Disulfiram b) Naltrexone c) Benzodiazepines |
a)500 mg once daily × 1 – 2 weeks, then 250 mg P.O. once daily b)50 mg P.O. once daily. c) dose varies on the basis of the specific agent, level of alcohol tolerance, history of past withdrawal, and presenting symptoms of withdrawal. |
a) Stop before and avoid all alcohol use while taking this prescription. Contraindicated
in patients with severe myocardial disease or coronary occlusion. Punishment when
people drink. b) Reduces the "high" from alcohol c) For detoxification only. |
Alcoholics Anonymous (A.A.) http://www.alcoholics-anonymous.org webcite Alanon, Alateen http://www.al-anon.org webcite Rational Recovery http://rational.org webcite Local resources for alcoholism treatment; groups and family therapy. |
| Opioids |
a) Naltrexone b) Methadone c) LAAM2 d) Buprenorphine The use of other opioids for the treatment of opioid dependence is a violation of federal law. |
a) 50 mg P.O., once daily. b) 20 – 120 mg P.O., once daily. c) 80 – 100 mg P.O., every other day. d) 4 to 16 mg/day sublingually for maintenance. |
a) Will precipitate withdrawal if taken within 7 to 10 days of last opioid use. b & c) Use for maintenance and detoxification tightly regulated by FDA d) Sublingual tablet approved by FDA for medical withdrawal and maintenance. C-III drug. |
Narcotics Anonymous (N.A.) http://www.na.org webcite Naranon http://www.naranon.com webcite Buprenorphine subscribers: http://buprenorphine.samhsa.gov webcite Local resources for substance abuse and addiction treatment and group and family therapy. |
|
|
||||
|
1 Nicotine Transdermal System 2 L-alpha-acetyl-methadol |
||||
|
Tommasello Harm Reduction Journal 2004 1:3 doi:10.1186/1477-7517-1-3 |
||||
